Lisavanbulin is showing potential as an effective chemotherapy in glioblastoma multiforme, one of the most aggressive and difficult to treat cancers. We publish a research note today following further data presented at the recent ESMO and ASCO cancer conferences.
Glioblastoma is a deadly cancer; mortality rates are high with a median life expectancy of only 14-15 months.
Lisavanbulin data have been extremely encouraging so far, and its development has caught the attention of several media and medical publications.
Basilea has adopted a targeted approach to glioblastoma, with lisavanbulin seeking to deliver a chemotherapy combining strong efficacy with reduced resistance. Basilea is examining the use of a predictive biomarker that could improve the identification of patients suitable for lisavanbulin treatment. Data so far suggest that the presence of the EB1 protein in patients' tumour tissue significantly improves outcomes. The use of this biomarker has the potential to reduce the risk of treatment failure, and data presented at recent cancer conferences supports EB1 use.
We await the results of the current Phase 2 trial, with an interim read-out expected in H2 2021. The potential for lisavanbulin is substantial, particularly if the EB1 approach is relevant to a broader range of cancers.
We have calculated a discounted cash flow fair value of CHF120 for Basilea. Further success with lisavanbulin will provide an important upside.
Please subscribe here to receive our research, articles and invitations as soon as they are available.
IMPORTANT:
Basilea Pharmaceutica is a client of Calvine Partners and as such, this publication is not independent and should be considered a marketing communication under FCA Rules. None of the information contained in this publication should be considered as any form of advice.